In January 2026 Novo Nordisk appointed Maziar Doustdar as chief executive officer, marking the first leadership transition since 2017. Doustdar, previously head of global commercial operations, has unveiled a refocused strategy centered on accelerating late-stage obesity and diabetes programmes. Under his guidance the company forecasts double-digit revenue growth in 2026, driven by expanded semaglutide volumes and margin improvement initiatives. Management targets at least 12% annual EPS growth, supported by disciplined operating expenses and optimized supply‐chain efficiencies across its six manufacturing sites.

The imminent rollout of oral Wegovy is a cornerstone of Novo Nordisk’s 2026 growth plan. Phase III data demonstrated a mean 15% body‐weight reduction over 16 weeks with gastrointestinal tolerability rates exceeding 80%, outperforming competing injectable regimens. With initial capacity to produce 10 million monthly doses, the company expects uptake in Europe and North America to generate approximately US$3 billion in sales by year-end. This launch directly challenges Eli Lilly’s pending oral GLP-1 candidate, which has encountered regulatory delays into late 2026. Novo Nordisk has secured supply agreements with three major pharmacy chains to ensure broad patient access and intends to leverage its direct‐to‐physician digital platform to drive off-label diabetes prescriptions.

Following a sharp 2025 correction that saw shares slide over 40%, Novo Nordisk has staged a robust rebound, reflecting renewed investor confidence in its diversified portfolio. The company’s R&D pipeline now includes six obesity programmes, with amycretin entering phase I trials after demonstrating 13% weight loss in healthy volunteers, and CagriSema progressing toward phase II readouts by mid-2026. Novo Nordisk allocates 18% of revenues to R&D, with capex earmarked for two new filling lines in Kalundborg and increased bioreactor capacity in the US. Management expects net debt to remain below 10% of market capitalization, preserving financial flexibility for bolt-on acquisitions in adjacent metabolic indications.